LiquidiaLQDA +1.83%67 Net Margin % is 39.79% as of Mar. 2026. GuruFocus rates LQDA with a GF Score™ of 67/100 and a GF Value™ of $218.97 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Liquidia ranks better than 57.11% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Liquidia's Net Income for the
three
months ended in Mar. 2026 was $52.9 Mil. Liquidia's Revenue for the
three
months ended in Mar. 2026 was $132.9 Mil. Therefore, Liquidia's net margin for the quarter that ended in Mar. 2026 was 39.79%.
The historical rank and industry rank for Liquidia's Net Margin % or its related term are showing as below:
LQDA'
s Net Margin % Range Over the Past 10 Years
Min: -8076.08 Med: -425.29 Max: 7.74
Current: 7.74
LQDA's Net Margin % is ranked better than 57.11% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs LQDA: 7.74
Liquidia (NAS:LQDA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Liquidia Net Margin % Related Terms
Liquidia Net Margin % Historical Data
* Premium members only.
The historical data trend for Liquidia's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liquidia Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liquidia's Net Margin % distribution charts can be found below:
* The bar in red indicates where Liquidia's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia (LQDA) has a Net Margin % of 39.79% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Liquidia and its competitors. According to the industry distribution chart, Liquidia ranks #410 out of 956 companies in the Drug Manufacturers industry, placing it in the top 42.9%.
Is Liquidia's Net Margin % too high?
Liquidia's current Net Margin % is 39.79%. The Drug Manufacturers industry median Net Margin % is 5.56. Liquidia's value of 39.79% is 615.6% above this industry median. Based on the distribution chart, Liquidia ranks #410 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Liquidia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's Net Margin % compare to HIMS and LNTH?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #410 out of 956 companies for Net Margin %. This puts Liquidia in the upper half of its industry. The industry median Net Margin % is 5.56. Liquidia's value of 39.79% is 615.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liquidia's current Net Margin % of 39.79% is 615.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Liquidia and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liquidia's current Net Margin % is 39.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $218.97, compared to a current price of $76.91 — trading 64.9% below its estimated fair value. The current Net Margin % is 39.79% and 615.6% above the Drug Manufacturers industry median of 5.56. Liquidia's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Liquidia (LQDA), the current Net Margin % is 39.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liquidia (LQDA) Overvalued in 2026?
Based on GuruFocus' analysis, Liquidia stock appears to be undervalued.
The current stock price of $76.91 is trading 64.9% below its estimated GF Value™ of $218.97.
GuruFocus considers Liquidia to be Possible Value Trap.
Key valuation signals for LQDA:
Net Margin %: 39.79%
GF Value™: $218.97 vs. price of $76.91 (64.9% below fair value)
Industry Position: 615.6% above the Drug Manufacturers median (#410 of 956)
No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score
Get the complete analysis for LQDA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LQDA has been successfully added to your 
